JP2007519631A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007519631A5 JP2007519631A5 JP2006547015A JP2006547015A JP2007519631A5 JP 2007519631 A5 JP2007519631 A5 JP 2007519631A5 JP 2006547015 A JP2006547015 A JP 2006547015A JP 2006547015 A JP2006547015 A JP 2006547015A JP 2007519631 A5 JP2007519631 A5 JP 2007519631A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- hydrogen
- alkyl
- phenyl
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims 47
- 239000001257 hydrogen Substances 0.000 claims 47
- 125000000217 alkyl group Chemical group 0.000 claims 31
- 150000002431 hydrogen Chemical class 0.000 claims 31
- -1 cyano, amino Chemical group 0.000 claims 24
- 150000001875 compounds Chemical class 0.000 claims 22
- 125000003118 aryl group Chemical group 0.000 claims 20
- 125000000623 heterocyclic group Chemical group 0.000 claims 17
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 16
- 125000003545 alkoxy group Chemical group 0.000 claims 16
- 125000003282 alkyl amino group Chemical group 0.000 claims 13
- 125000004663 dialkyl amino group Chemical group 0.000 claims 13
- 125000005843 halogen group Chemical group 0.000 claims 13
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 12
- 125000001424 substituent group Chemical group 0.000 claims 11
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims 10
- 125000002252 acyl group Chemical group 0.000 claims 9
- 125000003710 aryl alkyl group Chemical group 0.000 claims 9
- 125000004043 oxo group Chemical group O=* 0.000 claims 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 9
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 7
- 125000004076 pyridyl group Chemical group 0.000 claims 7
- 125000005059 halophenyl group Chemical group 0.000 claims 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 5
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 125000001188 haloalkyl group Chemical group 0.000 claims 4
- ZCOVXTNHLNZJRU-UHFFFAOYSA-N n-[(4-fluorophenyl)methyl]-4-(3-phenylindol-1-yl)sulfonylbenzamide Chemical compound C1=CC(F)=CC=C1CNC(=O)C1=CC=C(S(=O)(=O)N2C3=CC=CC=C3C(C=3C=CC=CC=3)=C2)C=C1 ZCOVXTNHLNZJRU-UHFFFAOYSA-N 0.000 claims 4
- LJQBYRXOLRROPZ-UHFFFAOYSA-N 4-(3-cyclopentylindol-1-yl)sulfonyl-n-[(4-fluorophenyl)methyl]benzamide Chemical compound C1=CC(F)=CC=C1CNC(=O)C1=CC=C(S(=O)(=O)N2C3=CC=CC=C3C(C3CCCC3)=C2)C=C1 LJQBYRXOLRROPZ-UHFFFAOYSA-N 0.000 claims 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 3
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 3
- 125000002619 bicyclic group Chemical group 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 3
- 125000001207 fluorophenyl group Chemical group 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 3
- 125000006517 heterocyclyl carbonyl group Chemical group 0.000 claims 3
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 3
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 3
- 229920006395 saturated elastomer Polymers 0.000 claims 3
- 230000000638 stimulation Effects 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 2
- 208000030814 Eating disease Diseases 0.000 claims 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- NVSLHEAGBJMNIK-UHFFFAOYSA-N [4-(2,3-dihydroindol-1-ylsulfonyl)phenyl]-(4-phenylpiperazin-1-yl)methanone Chemical compound C=1C=C(S(=O)(=O)N2C3=CC=CC=C3CC2)C=CC=1C(=O)N(CC1)CCN1C1=CC=CC=C1 NVSLHEAGBJMNIK-UHFFFAOYSA-N 0.000 claims 2
- KMOHVMFBXIPKHP-UHFFFAOYSA-N [4-(2,3-dihydroindol-1-ylsulfonyl)phenyl]-morpholin-4-ylmethanone Chemical compound C=1C=C(S(=O)(=O)N2C3=CC=CC=C3CC2)C=CC=1C(=O)N1CCOCC1 KMOHVMFBXIPKHP-UHFFFAOYSA-N 0.000 claims 2
- 125000004104 aryloxy group Chemical group 0.000 claims 2
- 125000004671 dialkylaminothiocarbonyl group Chemical group 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 235000014632 disordered eating Nutrition 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000003337 fertilizer Substances 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 230000037406 food intake Effects 0.000 claims 2
- 235000012631 food intake Nutrition 0.000 claims 2
- 125000004438 haloalkoxy group Chemical group 0.000 claims 2
- 125000003106 haloaryl group Chemical group 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical group 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 230000003287 optical effect Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 claims 1
- 125000006536 (C1-C2)alkoxy group Chemical group 0.000 claims 1
- UBJIIXJLBJGGDG-UHFFFAOYSA-N 4-(3-cyclopentylindol-1-yl)sulfonyl-n-(oxan-4-yl)benzamide Chemical compound C=1C=C(S(=O)(=O)N2C3=CC=CC=C3C(C3CCCC3)=C2)C=CC=1C(=O)NC1CCOCC1 UBJIIXJLBJGGDG-UHFFFAOYSA-N 0.000 claims 1
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 239000013078 crystal Substances 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- PQIOSYKVBBWRRI-UHFFFAOYSA-N methylphosphonyl difluoride Chemical group CP(F)(F)=O PQIOSYKVBBWRRI-UHFFFAOYSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- MEFNEHAZMVPNPF-UHFFFAOYSA-N n-(cyclopropylmethyl)-4-(3-phenylindol-1-yl)sulfonylbenzamide Chemical compound C=1C=C(S(=O)(=O)N2C3=CC=CC=C3C(C=3C=CC=CC=3)=C2)C=CC=1C(=O)NCC1CC1 MEFNEHAZMVPNPF-UHFFFAOYSA-N 0.000 claims 1
- DMIBVXYCEJOIJQ-UHFFFAOYSA-N n-(oxan-4-ylmethyl)-4-(3-phenylindol-1-yl)sulfonylbenzamide Chemical compound C=1C=C(S(=O)(=O)N2C3=CC=CC=C3C(C=3C=CC=CC=3)=C2)C=CC=1C(=O)NCC1CCOCC1 DMIBVXYCEJOIJQ-UHFFFAOYSA-N 0.000 claims 1
- TVFAHEGTZFKRKE-UHFFFAOYSA-N n-[(4-fluorophenyl)methyl]-4-[3-(oxan-4-yl)indol-1-yl]sulfonylbenzamide Chemical compound C1=CC(F)=CC=C1CNC(=O)C1=CC=C(S(=O)(=O)N2C3=CC=CC=C3C(C3CCOCC3)=C2)C=C1 TVFAHEGTZFKRKE-UHFFFAOYSA-N 0.000 claims 1
- UMPBSICZALFVFE-UHFFFAOYSA-N n-[(5-fluoropyridin-3-yl)methyl]-4-(3-phenylindol-1-yl)sulfonylbenzamide Chemical compound FC1=CN=CC(CNC(=O)C=2C=CC(=CC=2)S(=O)(=O)N2C3=CC=CC=C3C(C=3C=CC=CC=3)=C2)=C1 UMPBSICZALFVFE-UHFFFAOYSA-N 0.000 claims 1
- 125000003884 phenylalkyl group Chemical group 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 125000000547 substituted alkyl group Chemical group 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 0 CCC(CC)N1CCN(*)CC1 Chemical compound CCC(CC)N1CCN(*)CC1 0.000 description 7
- JVJMCIOGNAMETD-RNPBPNGMSA-N C/C=N\C=C/C=C Chemical compound C/C=N\C=C/C=C JVJMCIOGNAMETD-RNPBPNGMSA-N 0.000 description 2
- PBMFSQRYOILNGV-UHFFFAOYSA-N c1cnncc1 Chemical compound c1cnncc1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 2
- JYWDEIHOHORTHJ-ARJAWSKDSA-N C/C=C\[I]=N/N=C Chemical compound C/C=C\[I]=N/N=C JYWDEIHOHORTHJ-ARJAWSKDSA-N 0.000 description 1
- OWJIDQBBMFPTEP-UHFFFAOYSA-N C1=CC=CC2N=[I]C=CC12 Chemical compound C1=CC=CC2N=[I]C=CC12 OWJIDQBBMFPTEP-UHFFFAOYSA-N 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N C1CCOCC1 Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- PYCFYVIRXJRSDS-UHFFFAOYSA-N CCC(CC)N1CCCCC1 Chemical compound CCC(CC)N1CCCCC1 PYCFYVIRXJRSDS-UHFFFAOYSA-N 0.000 description 1
- RCDHHTINEDQWDI-UHFFFAOYSA-N CCC(CC)N1CCSCC1 Chemical compound CCC(CC)N1CCSCC1 RCDHHTINEDQWDI-UHFFFAOYSA-N 0.000 description 1
- WEBOPFRMJGAKPV-UHFFFAOYSA-N CCCC(CC)N1CCOCC1 Chemical compound CCCC(CC)N1CCOCC1 WEBOPFRMJGAKPV-UHFFFAOYSA-N 0.000 description 1
- JZDSOQSUCWVBMV-UHFFFAOYSA-N CCN(C(c1c2cccc1)=O)C2=O Chemical compound CCN(C(c1c2cccc1)=O)C2=O JZDSOQSUCWVBMV-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53224703P | 2003-12-23 | 2003-12-23 | |
| PCT/US2004/039763 WO2005066126A1 (en) | 2003-12-23 | 2004-12-13 | Cb1 modulator compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007519631A JP2007519631A (ja) | 2007-07-19 |
| JP2007519631A5 true JP2007519631A5 (https=) | 2008-02-07 |
Family
ID=34748790
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006547015A Pending JP2007519631A (ja) | 2003-12-23 | 2004-12-13 | Ｃｂ１モジュレーター化合物 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US7276516B2 (https=) |
| EP (1) | EP1699761B1 (https=) |
| JP (1) | JP2007519631A (https=) |
| AR (1) | AR047160A1 (https=) |
| AT (1) | ATE502009T1 (https=) |
| AU (1) | AU2004312311A1 (https=) |
| BR (1) | BRPI0418079A (https=) |
| CA (1) | CA2549396A1 (https=) |
| DE (1) | DE602004031875D1 (https=) |
| ES (1) | ES2360112T3 (https=) |
| IL (1) | IL176069A0 (https=) |
| NO (1) | NO20063381L (https=) |
| PE (1) | PE20050598A1 (https=) |
| SV (1) | SV2005001984A (https=) |
| TW (1) | TW200522944A (https=) |
| WO (1) | WO2005066126A1 (https=) |
| ZA (1) | ZA200605159B (https=) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE521512C2 (sv) | 2001-06-25 | 2003-11-11 | Niconovum Ab | Anordning för administrering av en substans till främre delen av en individs munhåla |
| ES2285233T3 (es) | 2002-12-20 | 2007-11-16 | Niconovum Ab | Un material en particulas que contiene nicotina y celulosa microcristalina fisicamente y quimicamente estable. |
| GB0516379D0 (en) * | 2005-08-09 | 2005-09-14 | Glaxo Group Ltd | Compounds |
| US7544676B2 (en) * | 2005-11-10 | 2009-06-09 | Adolor Corporation | Sulfamoyl benzamides and methods of their use |
| FR2893615B1 (fr) * | 2005-11-18 | 2008-03-07 | Sanofi Aventis Sa | Derives de 3-acylindole, leur preparation et leur application en therapeutique |
| CA2637531A1 (en) | 2006-02-17 | 2007-08-30 | Memory Pharmaceuticals Corporation | Compounds having 5-ht6 receptor affinity |
| US9402809B2 (en) | 2006-03-16 | 2016-08-02 | Niconovum Usa, Inc. | Snuff composition |
| WO2007138611A1 (en) * | 2006-05-30 | 2007-12-06 | Suven Life Sciences Limited | 3-(heterocyclyl)-n-(arylsulfonyl)indole derivatives as functional 5-ht6 ligands |
| US8309595B2 (en) * | 2007-07-13 | 2012-11-13 | Board Of Regents, The University Of Texas System | Hydrazone modulators of cannabinoid receptors |
| US9079854B2 (en) | 2007-07-13 | 2015-07-14 | The Cleveland Clinic Foundation | Hydrazone modulators of cannabinoid receptors |
| US7759335B2 (en) * | 2008-01-31 | 2010-07-20 | Jenrm Discovery, Inc. | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes |
| US20100056491A1 (en) * | 2008-08-29 | 2010-03-04 | Memory Pharmaceuticals Corporation | 4'-amino cyclic compounds having 5-ht6 receptor affinity |
| WO2010032257A1 (en) * | 2008-09-17 | 2010-03-25 | Suven Life Sciences Limited | Aryl indolyl sulfonamide compounds and their use as 5-ht6 ligands |
| WO2010047982A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| JP5557845B2 (ja) | 2008-10-31 | 2014-07-23 | メルク・シャープ・アンド・ドーム・コーポレーション | 糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体 |
| RU2561132C2 (ru) * | 2009-06-29 | 2015-08-20 | Аджиос Фармасьютикалз, Инк. | Производные хинолинсульфонамидов и их применение для модулирования пкм2 активности |
| MX336731B (es) | 2010-01-28 | 2016-01-28 | Harvard College | Composiciones y metodos para potenciar la actividad de proteasoma. |
| US8895596B2 (en) | 2010-02-25 | 2014-11-25 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
| BR112013021236B1 (pt) | 2011-02-25 | 2021-05-25 | Merck Sharp & Dohme Corp | composto derivado de benzimidazol, e, composição |
| JP2014511894A (ja) | 2011-04-20 | 2014-05-19 | グラクソ グループ リミテッド | 抗結核化合物としてのテトラヒドロピラゾロ［１，５‐ａ］ピリミジン |
| DK2707101T3 (da) * | 2011-05-12 | 2019-05-13 | Proteostasis Therapeutics Inc | Proteostaseregulatorer |
| AP2014007738A0 (en) * | 2012-01-16 | 2014-07-31 | Bayer Ip Gmbh | Spiroindoline derivatives as gonadotropin-releasing hormone receptor antagonists |
| US9527875B2 (en) | 2012-08-02 | 2016-12-27 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| TW201410243A (zh) * | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療大麻素受體型１（ｃｂ１）媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| US20140206667A1 (en) | 2012-11-14 | 2014-07-24 | Michela Gallagher | Methods and compositions for treating schizophrenia |
| US9849135B2 (en) | 2013-01-25 | 2017-12-26 | President And Fellows Of Harvard College | USP14 inhibitors for treating or preventing viral infections |
| RU2015140066A (ru) | 2013-02-22 | 2017-03-30 | Мерк Шарп И Доум Корп. | Противодиабетические бициклические соединения |
| WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
| RU2582393C2 (ru) * | 2013-07-31 | 2016-04-27 | Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" | Способ лечения ожирения и сопутствующих метаболических расстройств |
| RU2557971C2 (ru) * | 2013-07-31 | 2015-07-27 | Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" | Способ воздействия на функциональную активность каннабиноидного рецептора |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| WO2015073528A1 (en) | 2013-11-12 | 2015-05-21 | Proteostasis Therapeutics, Inc. | Proteasome activity enhancing compounds |
| ES2842592T3 (es) * | 2014-05-19 | 2021-07-14 | Boehringer Ingelheim Animal Health Usa Inc | Compuestos antihelmínticos |
| CA2949229A1 (en) * | 2014-05-23 | 2015-11-26 | F. Hoffmann-La Roche Ag | Benzene sulfonamide derivatives and their use as rorc modulators |
| JP7053054B2 (ja) | 2016-04-15 | 2022-04-12 | エスアールイー ウェルネス，インク． | 大麻注入甘味料及び他の組成物 |
| JP2019511580A (ja) | 2016-04-15 | 2019-04-25 | エスアールイー ウェルネス インク．Ｓｒｅ Ｗｅｌｌｎｅｓｓ Ｉｎｃ． | 乳化剤を使用して大麻油を親水性にする方法及び関連するカンナビノイド組成物 |
| US20220087972A9 (en) | 2016-04-15 | 2022-03-24 | Sre Wellness, Inc. | Cannabinoid Compositions |
| CN106349196B (zh) * | 2016-08-26 | 2019-01-04 | 江苏克胜作物科技有限公司 | 一种呋虫胺的合成方法 |
| US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| WO2018210658A1 (en) * | 2017-05-15 | 2018-11-22 | Basf Se | Heteroaryl compounds as agrochemical fungicides |
| AU2019391109A1 (en) * | 2018-12-07 | 2021-06-24 | Opiant Pharmaceuticals, Inc. | Compositions and methods for treating acute cannabinoid overdose with a cannabinoid receptor antagonist |
| WO2022032073A2 (en) * | 2020-08-07 | 2022-02-10 | Casma Therapeutics, Inc. | Trpml modulators |
| CN113861194B (zh) * | 2021-11-10 | 2022-07-05 | 英维沃化工科技(广州)有限公司 | 一种含吡咯并吡啶双酰胺咪唑类化合物及其制备方法和应用 |
| US20250333406A1 (en) * | 2022-05-31 | 2025-10-30 | Lysoway Therapeutics, Inc. | Sulfonyl cyclic derivatives, and compositions and methods thereof |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3630200A (en) | 1969-06-09 | 1971-12-28 | Alza Corp | Ocular insert |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US5081122A (en) | 1990-03-05 | 1992-01-14 | Sterling Drug Inc. | Antiglaucoma compositions containing 4-arylcarbonyl-1-(4-morpholinyl)-lower-alkyl)-1H-indoles and method of use thereof |
| US5112820A (en) | 1990-03-05 | 1992-05-12 | Sterling Drug Inc. | Anti-glaucoma compositions containing 2- and 3-aminomethyl-6-arylcarbonyl- or 6-phenylthio-2,3-dihydropyrrolo-(1,2,3-de)-1,4-benzoxazines and method of use thereof |
| US5013837A (en) | 1990-03-08 | 1991-05-07 | Sterling Drug Inc. | 3-Arylcarbonyl-1H-indole-containing compounds |
| US4973587A (en) | 1990-03-08 | 1990-11-27 | Sterling Drug Inc. | 3-arylcarbonyl-1-aminoalkyl-1H-indole-containing antiglaucoma method |
| FR2692575B1 (fr) | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| US5292736A (en) | 1993-02-26 | 1994-03-08 | Sterling Winthrop Inc. | Morpholinoalkylindenes as antiglaucoma agents |
| FR2714057B1 (fr) | 1993-12-17 | 1996-03-08 | Sanofi Elf | Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant. |
| US5532237A (en) | 1995-02-15 | 1996-07-02 | Merck Frosst Canada, Inc. | Indole derivatives with affinity for the cannabinoid receptor |
| FR2741621B1 (fr) | 1995-11-23 | 1998-02-13 | Sanofi Sa | Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant |
| EP0887340A4 (en) | 1996-02-06 | 2000-03-29 | Japan Tobacco Inc | CHEMICAL COMPOUNDS AND THEIR PHARMACEUTICAL USE |
| DE69822449T2 (de) | 1997-01-21 | 2005-01-27 | Smithkline Beecham Corp. | Neue cannabinoidrezeptor-modulatoren |
| TR199902012T2 (xx) | 1997-02-21 | 2000-01-21 | Bayer Aktiengesellschaft | Arils�lfonamidler ve analoglar� |
| EP0979228A4 (en) | 1997-03-18 | 2000-05-03 | Smithkline Beecham Corp | CANNABINOID RECEPTOR AGONISTS |
| FR2761266B1 (fr) | 1997-03-28 | 1999-07-02 | Sanofi Sa | Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates |
| FR2761265B1 (fr) | 1997-03-28 | 1999-07-02 | Sanofi Sa | Composition pharmaceutique pour l'administration orale d'un derive du n-piperidino-3-pyrazolecarboxamide, de ses sels et de leurs solvates |
| KR20010021696A (ko) | 1997-07-11 | 2001-03-15 | 미즈노 마사루 | 퀴놀린 화합물 및 그의 의약용도 |
| HN1998000027A (es) | 1998-08-19 | 1999-06-02 | Bayer Ip Gmbh | Arilsulfonamidas y analagos |
| DE19837627A1 (de) | 1998-08-19 | 2000-02-24 | Bayer Ag | Neue Aminosäureester von Arylsulfonamiden und Analoga |
| WO2000030683A1 (en) * | 1998-11-19 | 2000-06-02 | Shionogi & C0., Ltd. | Preventives and/or remedies for central nervous system diseases containing compounds having txa2 receptor antagonism and/or txa2 synthase inhibitory effect |
| WO2001058869A2 (en) * | 2000-02-11 | 2001-08-16 | Bristol-Myers Squibb Company | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases |
| US6566356B2 (en) | 2000-03-03 | 2003-05-20 | Aventis Pharma S.A. | Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation |
| AU2001296193B2 (en) * | 2000-10-20 | 2006-04-27 | Biovitrum Ab | 2-, 3-, 4-, or 5-substituted-N1-(benzensulfonyl)indoles and their use in therapy |
| AU2002231098A1 (en) * | 2000-12-15 | 2002-06-24 | Emory University | Nonpeptide agonists and antagonists of vasopressin receptors |
| WO2003007887A2 (en) | 2001-07-20 | 2003-01-30 | Merck & Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
| HRP20030913A2 (en) | 2001-09-21 | 2004-06-30 | Solvay Pharm Bv | 4,5-dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity |
| TWI231757B (en) | 2001-09-21 | 2005-05-01 | Solvay Pharm Bv | 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity |
| GB0202679D0 (en) * | 2002-02-05 | 2002-03-20 | Glaxo Group Ltd | Novel compounds |
| EP1506960B1 (en) * | 2003-08-07 | 2011-04-06 | National Health Research Institutes | Indole compounds as inhibitors of tubulin polymerisation for the treatment of angiogenesis-related disorders |
-
2004
- 2004-11-23 TW TW093136000A patent/TW200522944A/zh unknown
- 2004-12-10 PE PE2004001249A patent/PE20050598A1/es not_active Application Discontinuation
- 2004-12-13 US US10/596,495 patent/US7276516B2/en not_active Expired - Fee Related
- 2004-12-13 EP EP04812310A patent/EP1699761B1/en not_active Expired - Lifetime
- 2004-12-13 JP JP2006547015A patent/JP2007519631A/ja active Pending
- 2004-12-13 WO PCT/US2004/039763 patent/WO2005066126A1/en not_active Ceased
- 2004-12-13 CA CA002549396A patent/CA2549396A1/en not_active Abandoned
- 2004-12-13 AU AU2004312311A patent/AU2004312311A1/en not_active Abandoned
- 2004-12-13 BR BRPI0418079-8A patent/BRPI0418079A/pt not_active IP Right Cessation
- 2004-12-13 DE DE602004031875T patent/DE602004031875D1/de not_active Expired - Lifetime
- 2004-12-13 AT AT04812310T patent/ATE502009T1/de not_active IP Right Cessation
- 2004-12-13 ES ES04812310T patent/ES2360112T3/es not_active Expired - Lifetime
- 2004-12-21 AR ARP040104819A patent/AR047160A1/es unknown
- 2004-12-22 SV SV2004001984A patent/SV2005001984A/es not_active Application Discontinuation
-
2006
- 2006-05-31 IL IL176069A patent/IL176069A0/en unknown
- 2006-06-22 ZA ZA200605159A patent/ZA200605159B/en unknown
- 2006-07-21 NO NO20063381A patent/NO20063381L/no not_active Application Discontinuation
-
2007
- 2007-08-17 US US11/840,417 patent/US7595339B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007519631A5 (https=) | ||
| AR047160A1 (es) | Compuestos moduladores de cb1 | |
| RU2388750C2 (ru) | Ингибиторы фосфодиэстеразы 4, включая аналоги n-замещенного диариламина | |
| RU2436776C2 (ru) | ДИАРИЛАМИН-СОДЕРЖАЩИЕ СОЕДИНЕНИЯ, КОМПОЗИЦИИ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРОВ с-КIT | |
| JP2007513901A5 (https=) | ||
| NO20064065L (no) | Diaminopyrimidiner som P2X3 og P2X2/3 antagonister | |
| JP2007519754A5 (https=) | ||
| NO20073366L (no) | 1,6-substituert (3R,6R)-3-(2,3-dihydro-1H-inden-2-yl)-2,5-piperazindionderivater som oksytocinreceptorantagonister for behandling av for tidlige veer, dysmenorri og endometriose | |
| NO20161634A1 (no) | 3-Z-[1-(4-(N-((4-metyl-piperazin-1-yl)-metylkarbonyl)-N-metyl-amino)-anilino)-1-fenyl-metylen]-6-metoksykarbonyl-2-indolinon, tautomerene, diastereomerene, enantiomerene, blandinger derav og saltene derav, og i kombinasjon med en ytterligere farmakologisk aktiv substans, for anvendelse i forebygging eller behandling av fibrose ved revmatoid artritt | |
| JP2010538076A5 (https=) | ||
| RU2004132844A (ru) | Производные бензамида, полехные в качестве ингибиторов деацетилазы гистонов | |
| RU2010138577A (ru) | ИНГИБИТОРЫ РЕЦЕПТОРА ХЕМОКИНА CxCR3 | |
| JP2008528467A5 (https=) | ||
| RU2007134380A (ru) | Антибактериальные производные пиперидина | |
| JP2007501831A5 (https=) | ||
| NO20063470L (no) | Tetrazolforbindelser og deres anvendelse av metabotrofe glutamatreseptorantagonister | |
| JP2017502940A5 (https=) | ||
| PE20040702A1 (es) | Heterociclos diarilicos sustituidos y procedimiento para su preparacion como medicamentos | |
| TW200517109A (en) | Substituted pyridinones | |
| NO20063599L (no) | Ytterligere heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister | |
| JP2005526723A5 (https=) | ||
| MX2010005717A (es) | Derivados de isoxazolo-piridina. | |
| JP2011512412A5 (https=) | ||
| ES2390459T3 (es) | Antagonistas de receptores de opioides | |
| JP2020534274A5 (https=) |